Hyemin Chung

Dr. Hyemin Chung

Chung-Ang University Hospital, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
HSHyeonji Seo
Hyeonji Seo
HKHaein Kim
Haein Kim
SBSeongman Bae
Seongman Bae
SPSeonghee Park
Seonghee Park
HCHyemin Chung
Hyemin Chung
YCYong Pil Chong
Yong Pil Chong
Seo H, et al. Infect Chemother. 2022 Mar;54(1):102-113. https://doi.org/10.3947/ic.2021.0142

1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHyemin Chung
Hyemin Chung
HSHyeonji Seo
Hyeonji Seo
SPSunghee Park
Sunghee Park
HKHaein Kim
Haein Kim
JJJiwon Jung
Jiwon Jung
MKMin Jae Kim
Min Jae Kim
Chung H, et al. J Korean Med Sci. 2021 Jun;36(25):e181. https://doi.org/10.3346/jkms.2021.36.e181

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHyemin Chung
Hyemin Chung
EKEun Ok Kim
Eun Ok Kim
SKSung-Han Kim
Sung-Han Kim
JJJiwon Jung
Jiwon Jung
Chung H, et al. J Korean Med Sci. 2020 Nov;35(50):e431. https://doi.org/10.3346/jkms.2020.35.e431

27 January 2022 in Viruses
Verified
Journal Article
Open access
PDF file
HCHyemin Chung
Hyemin Chung
EKEunsil Kim
Eunsil Kim
BKBomin Kwon
Bomin Kwon
YCYeong Geon Cho
Yeong Geon Cho
SBSeongman Bae
Seongman Bae
KGKorea SFTS Study Group
Korea SFTS Study Group
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne disease in East Asia that is causing high mortality. The Gn glycoprotein of the SFTS virus (SFTSV) has been considered to be an essential target for virus neutralization. However, data on anti-Gn glycoprotein antibody kinetics are limited. Therefore, we investigated the kinetics of Gn-specific antibodies compared to those of nucleocapsid protein (NP)-specific antibodies. A multicenter prospective study was performed in South Korea from January 2018 to September 2021. Adult patients with SFTS were enrolled. Anti-Gn-specific IgM and IgG were measured using an enzyme-linked immunosorbent assay. A total of 111 samples from 34 patients with confirmed SFTS were analyzed. Anti-Gn-specific IgM was detected at days 5–9 and peaked at day 15–19 from symptom onset, whereas the anti-NP-specific IgM titers peaked at days 5–9. Median seroconversion times of both anti-Gn- and NP-specific IgG were 7.0 days. High anti-Gn-specific IgG titers were maintained until 35–39 months after symptom onset. Only one patient lost their anti-Gn-specific antibodies at 41 days after symptom onset. Our data suggested that the anti-Gn-specific IgM titer peaked later than anti-NP-specific IgM, and that anti-Gn-specific IgG remain for at least 3 years from symptom onset.

13 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
JPJoung Ha Park
Joung Ha Park
HCHyemin Chung
Hyemin Chung
MKMin-Chul Kim
Min-Chul Kim
Seong-Ho ChoiSeong-Ho Choi
Seong-Ho Choi
JCJin-Won Chung
Jin-Won Chung
We compared immune responses against the omicron variant of SARS-CoV-2 after a third dose of the coronavirus disease 2019 (COVID-19) vaccine between people living with human immunodeficiency (PLWH) and healthcare workers (HCWs). In this prospective observational study, PLWH and HCWs vaccinated with at least two doses of vaccine were enrolled. We analyzed neutralizing responses using the GenScript SARS-CoV-2 surrogate virus neutralization test kit. Twenty-nine PLWH and 114 HCWs were included to analyze immune responses after the third vaccination. Most PLWH (86.2%) had fully suppressed viral loads and CD4 T cell counts were well-controlled (median 670.0 cells/μL). The neutralizing responses against the omicron variant in PLWH were not significantly different from those in HCWs (43.94% vs. 51.77%, p = 0.42). However, neutralizing responses against the omicron variant were significantly impaired by about 50% compared with wild type SARS-CoV-2 in PLWH (43.94% vs. 97.46%, p < 0.001) and HCWs (51.77% vs. 97.74%, p < 0.001). Although neutralizing responses against the omicron variant in well-controlled PLWH were comparable to those of HCWs, the responses were much lower than those against wild type in both PLWH and HCWs. Therefore, the risk of breakthrough SARS-CoV-2 infection due to the currently circulating omicron variant is still high despite three doses of vaccine in PLWH and will not differ from HCWs.

1 January 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
HCHyemin Chung
Hyemin Chung
SCSung-Kwan Cho
Sung-Kwan Cho
JJJiyeon Joo
Jiyeon Joo
SKSung-Han Kim
Sung-Han Kim
EKEun Ok Kim
Eun Ok Kim
SKSung-Han Kim
Sung-Han Kim
Chung H, et al. Infect Chemother. 2023 Aug;55:e35. https://doi.org/10.3947/ic.2023.0049